Review Reports
- Ann-Kathrin Lederer 1,2,
- Constantin-Leonard Jacob Kessler 1 and
- Thomas J. Musholt 1,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe pitfalls of calcitonin as a tumor marker: real-life data of patients with elevated basal calcitonin levels but without evidence of medullary thyroid carcinoma.
I enjoyed reading this paper. I can usually find something in reviewed papers to cause concern but, try as I might, I could not find serious fault with this study.
It doesn’t make claims that it cannot substantiate but rather describes a real-world experience of a TMC “marker” whose specificity is not always as high as we might like. It concentrates on what happens to patients with calcitonin measurements that are not considered to be diagnostic and that is an important area given the potential sequelae (both clinical and psychological) of getting this wrong.
The authors have noted all the limitations of the study that had occurred to me in reading it. References are clear, relevant and full and the paper is easy to read and well planned and thought out.
I especially enjoyed their salutary message about not sharpening the knives immediately when faced with a raised calcitonin. It’s rare to laugh aloud when reviewing scientific papers but I did then!
Nicely done, folks!
Proof reading suggestions: Note the inclusion of an errant dash (-) in lines 497, 498 and 500.
Author Response
We would like to thank you for the very positive and encouraging assessment of our manuscript! The errant dashes noted in lines 497, 498, and 500 have been corrected in the revised manuscript. Thank you again for your constructive and supportive feedback.
Reviewer 2 Report
Comments and Suggestions for Authors1. The research design is a retrospective study using heterogeneous sources of data (clinical records and ICD-based identification) with no explanation of the selection process and patient flow. There is a need to include/exclusion flowchart and explain how the final size of the cohort was obtained (167 vs more ICD patients).
2. There is a lack of methodological description of the process of calcitonin measurement such as the type of assay, detection limits, laboratory calibration, and the fact that the same assay was used throughout the study period (20072025) is important because of the known assay variability and interference.
3. Possible confounding variables that can raise calcitonin (e.g., proton pump inhibitors, kidney disease, smoking status, autoimmune thyroid disease, neuroendocrine tumors) were not carefully analyzed and controlled.
4. The argument of conducting surgery among 77% of the patients whose calcitonin elevation is mostly mild (less than 20 pg/mL) is not well explained and the clinical decision criteria of conducting surgery should be clearly explained.
5. Presentation of the statistical analysis is inadequate; the study fails to indicate hypothesis testing, confidence intervals, regression analysis or subgroup comparison and this reduces the extent to which the results can be interpreted.
6. The description of the data is incongruent: the original number of patients is given as 345, and the number of patients finally analyzed is in 167, though it was also stated that 29 ICD cases were also observed, which should be explained.
7. The time of follow-up is very short (median 4.6 months) when assessing the long-term outcomes of calcitonin elevation, which undermines inferences about the risk of malignancy and clinical significance.
8. There are no comparison groups (e.g. normal calcitonin patients or confirmed MTC cases) so it is hard to put findings into context and determine diagnostic cutoffs.
9. The discussion lacks adequate comparison of the results with existing literature about the calcitonin screening levels and false-positive rates especially in the range of <20 pg/mL.
10. The problem of assay interference and false positives is not discussed in detail, but only briefly; further laboratory validation or repeat testing procedures are to be outlined.
11. The prevalence of goiter is high (86) but not compared with calcitonin levels or surgical outcomes, which would have provided an opportunity to have clinically relevant subgroup analysis.
12. No description of ethical approval procedures and the patient consent is clearly mentioned even though retrospective patient records over several years have been used.
13. To enhance data transparency, tables that summarize the patient characteristics, distribution of calcitonin levels, outcome of surgery, and follow-up status should be included.
14. The conclusions themselves seem stronger than justified by the little follow-up and the absence of statistical analysis and thus would benefit moderation to indicate the study limitations.
15. I have carefully chosen the cited references based on the specific gaps identified in the manuscript, particularly in the introduction and literature review sections. These references provide essential background, address the missing foundational context, and enhance the discussion with relevant prior work. Additionally, I confirm that these are not self-citations but rather the most suitable and high-impact sources that align with the study’s objectives.
Uncertainty of Disease Diagnosis in Elderly Cancer Patients; The relationship between hospital ownership, in-hospital mortality, and medical expenses: an analysis of three common conditions in China; NF-κB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity; Calcitonin gene-related peptide inhibits the cardiac fibroblasts senescence in cardiac fibrosis via up-regulating klotho expression; Disorders of cancer metabolism: The therapeutic potential of cannabinoids; Microcystins Exposure Associated with Blood Lipid Profiles and Dyslipidemia: A Cross-Sectional Study in Hunan Province, China; Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder; Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy; Nanomaterials for bone metastasis; Exploring the Mechanism of Centipeda minima in Treating Nasopharyngeal Carcinoma Based on Network Pharmacology
Author Response
We thank you for your careful assessment and helpful comments, which have improved the manuscript!
- The research design is a retrospective study using heterogeneous sources of data (clinical records and ICD-based identification) with no explanation of the selection process and patient flow. There is a need to include/exclusion flowchart and explain how the final size of the cohort was obtained (167 vs more ICD patients).
Response: We thank you for your comment. We agree that the patient flow was not sufficiently clear. We have therefore revised the description and improved Figure 1 to clearly illustrate the screening and exclusion process, including the combination of laboratory screening and ICD-based identification.
- There is a lack of methodological description of the process of calcitonin measurement such as the type of assay, detection limits, laboratory calibration, and the fact that the same assay was used throughout the study period (20072025) is important because of the known assay variability and interference.
Response: We have now included a detailed description of the calcitonin measurement methods in the Methods section (line 150-164).
- Possible confounding variables that can raise calcitonin (e.g., proton pump inhibitors, kidney disease, smoking status, autoimmune thyroid disease, neuroendocrine tumors) were not carefully analyzed and controlled.
Response: Thank you for this important comment. Potential confounding factors known to influence calcitonin levels (e.g., thyroiditis, hyperparathyroidism, renal insufficiency, smoking status, medication use) were extracted from the medical records whenever available. However, due to the retrospective nature of the study and incomplete documentation in some patients, particularly those who were not surgically treated, it was not possible to systematically control for all potential confounders. We have clarified this aspect in the Methods (line 125-129) and Discussion (line 547-548) sections.
- The argument of conducting surgery among 77% of the patients whose calcitonin elevation is mostly mild (less than 20 pg/mL) is not well explained and the clinical decision criteria of conducting surgery should be clearly explained.
Response: Surgery was not performed solely based on mild calcitonin elevation. In most cases, the indication for thyroidectomy was based on standard clinical criteria, such as suspicious thyroid nodules on ultrasound, indeterminate or suspicious cytology, nodule growth, compressive symptoms, or clinical suspicion of malignancy. We have clarified the clinical decision criteria for surgery in the Methods section (line 133-137).
- Presentation of the statistical analysis is inadequate; the study fails to indicate hypothesis testing, confidence intervals, regression analysis or subgroup comparison and this reduces the extent to which the results can be interpreted.
Response: We thank you for this important comment. The study was designed as an exploratory retrospective cohort analysis aimed at characterizing patients with elevated basal serum calcitonin levels without histologically confirmed MTC. We have now explicitly stated the underlying hypothesis in Methods (line 102-105). Due to the exploratory design of the study and the very low number of clinically relevant outcome events, multivariable regression analyses were not performed, as such models would not be statistically meaningful.
- The description of the data is incongruent: the original number of patients is given as 345, and the number of patients finally analyzed is in 167, though it was also stated that 29 ICD cases were also observed, which should be explained.
Response: We thank you for this comment. The apparent discrepancy arises from the fact that the 345 values refer to calcitonin measurements rather than individual patients. After removal of duplicate measurements, 244 individual patients remained. We have clarified this in the revised manuscript and further detailed the identification of additional patients via ICD search and the merging of both datasets (line 186-206 and Figure 1).
- The time of follow-up is very short (median 4.6 months) when assessing the long-term outcomes of calcitonin elevation, which undermines inferences about the risk of malignancy and clinical significance.
Response: We agree that the median follow-up time is relatively short to assess long-term outcomes and the potential development of medullary thyroid carcinoma. We have clarified this limitation in the Discussion and emphasized that our findings should be interpreted primarily as a descriptive real-world characterization rather than an assessment of long-term malignancy risk (line 536-543).
- There are no comparison groups (e.g. normal calcitonin patients or confirmed MTC cases) so it is hard to put findings into context and determine diagnostic cutoffs.
Response: Thank you for this important comment. We agree that the absence of a control group limits the ability to derive diagnostic cutoffs or to directly compare calcitonin levels across different clinical scenarios. However, the aim of the present study was not to establish diagnostic thresholds, but rather to characterize patients with elevated basal calcitonin levels without histologically confirmed MTC in a real-world clinical setting. Our cohort therefore specifically focuses on this clinically challenging subgroup of patients in whom calcitonin is elevated but MTC is not confirmed. We added the lack of a comparison cohort as a limitation in the Discussion (line 540-544).
- The discussion lacks adequate comparison of the results with existing literature about the calcitonin screening levels and false-positive rates especially in the range of <20 pg/mL.
Response: We have expanded the Discussion section to include a more detailed comparison of our findings with existing literature (line 466-480).
- The problem of assay interference and false positives is not discussed in detail, but only briefly; further laboratory validation or repeat testing procedures are to be outlined.
Response: We agree that assay interference represents a relevant cause of falsely elevated calcitonin levels and deserves further discussion. Therefore, we have expanded the Discussion section (line 490-496).
- The prevalence of goiter is high (86) but not compared with calcitonin levels or surgical outcomes, which would have provided an opportunity to have clinically relevant subgroup analysis.
Response: We performed the suggested subgroup analysis comparing patients with and without goiter regarding basal calcitonin levels. No relevant difference in basal calcitonin levels was observed between patients with and without goiter (median 12.5 pg/ml vs. 12.8 pg/ml). This analysis has now been added to the Results section of the manuscript (line 379-380).
- No description of ethical approval procedures and the patient consent is clearly mentioned even though retrospective patient records over several years have been used.
Response: According to the regulations of the Ethics Committee of Rhineland-Palatinate, retrospective analyses of anonymized routinely collected clinical data do not require formal ethical approval. We have clarified this point in the Methods section (line 102-105).
- To enhance data transparency, tables that summarize the patient characteristics, distribution of calcitonin levels, outcome of surgery, and follow-up status should be included.
Response: Thank you for this helpful suggestion. We have added an additional table (now Table 3) summarizing the distribution of calcitonin levels, surgical outcomes, and follow-up status. Patient characteristics were already summarized in Tables 1 of the original manuscript.
- The conclusions themselves seem stronger than justified by the little follow-up and the absence of statistical analysis and thus would benefit moderation to indicate the study limitations.
Response: We agree that the conclusions in the original version were phrased too strongly considering the limited follow-up and the descriptive nature of the analysis. We have therefore moderated the wording of the Conclusions and added a statement addressing the retrospective design, limited follow-up, and lack of inferential statistical analysis as study limitations in the revised manuscript.
- I have carefully chosen the cited references based on the specific gaps identified in the manuscript, particularly in the introduction and literature review sections. These references provide essential background, address the missing foundational context, and enhance the discussion with relevant prior work. Additionally, I confirm that these are not self-citations but rather the most suitable and high-impact sources that align with the study’s objectives.
Uncertainty of Disease Diagnosis in Elderly Cancer Patients; The relationship between hospital ownership, in-hospital mortality, and medical expenses: an analysis of three common conditions in China; NF-κB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity; Calcitonin gene-related peptide inhibits the cardiac fibroblasts senescence in cardiac fibrosis via up-regulating klotho expression; Disorders of cancer metabolism: The therapeutic potential of cannabinoids; Microcystins Exposure Associated with Blood Lipid Profiles and Dyslipidemia: A Cross-Sectional Study in Hunan Province, China; Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder; Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy; Nanomaterials for bone metastasis; Exploring the Mechanism of Centipeda minima in Treating Nasopharyngeal Carcinoma Based on Network Pharmacology
Response: We thank you for providing suggested references. We have carefully reviewed all the listed studies; however, none of them appeared to be directly relevant to the clinical context of basal calcitonin elevation and medullary thyroid carcinoma addressed in our study. Therefore, they were not included in the revised manuscript.
Reviewer 3 Report
Comments and Suggestions for AuthorsThank you for the opportunity to review this manuscript. The topic is clinically relevant and the study design is appropriate; the methods and results are generally clear, and the conclusions are supported by the data. To strengthen the paper, please clarify the patient selection process (with precise inclusion/exclusion criteria and, ideally, a simple flowchart), and report follow-up completeness and how missing data were handled. I also suggest defining outcomes/complications more explicitly, improving the structure of the Results (baseline vs outcomes vs complications), and expanding the limitations section regarding the retrospective, single-centre design and potential selection bias. Finally, minor English and formatting issues should be corrected with careful proofreading.
Comments on the Quality of English LanguageThe English is generally understandable, but it would benefit from careful proofreading to improve clarity and consistency. I noticed several minor grammatical and stylistic issues, occasional awkward phrasing, and some formatting/line-break problems (e.g., broken words). A light language edit would make the manuscript easier to read and more polished.
Author Response
We thank you for the constructive comments. We have revised the manuscript as follows: The inclusion and exclusion criteria have been clarified, and Figure 1 has been updated to provide a clear and simple overview of patient flow, including laboratory-based and ICD-based identification. Missing follow-up data are now discussed in the Discussion section (line 536-543). The Discussion now emphasizes also the retrospective, single-centre design and potential selection bias. No imputation was performed (added to Methods, line 172-173). An additional Table 3 has been added summarizing calcitonin levels, surgical outcomes, and follow-up status to improve clarity and facilitate comparison. English and formatting have been carefully revised throughout the manuscript.